Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

In this article, the authors detail their experience with AltrenoTM, a new topical retinoid lotion used for treating mild to moderate acne, reporting clinical effectiveness and satisfactory tolerability among patients of various ages, including children as young as 9.

In this study, the researchers reported that calcipotriol pre-treatment made photodynamic therapy more effective and safe than conventional treatment for actinic keratosis on the scalp, improving long-term clearance rates, especially for Grade II lesions. However, they suggested larger trials are necessary to corroborate these findings.

This paper from dermatology experts discusses their affiliations and declares no significant commercial interests, but it reports no research findings.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that acetyl zingerone methyl ether (MAZ) in hair dyes and haircare products may reduce oxidative damage, improve hair condition, and enhance the longevity and quality of dyed hair color.

This study reported that topical azelaic acid cream 20% demonstrated statistically significant efficacy in treating localized alopecia areata of the scalp over 12 weeks, comparable to topical clobetasol ointment 0.05%, suggesting it as a potential therapeutic option.

A man developed a rare skin condition and drug-induced lupus, highlighting the need for biopsy in diagnosing skin issues caused by sunlight.

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

This study found that daily use of an emollient PLUS containing ADE-G1 significantly reduced xerosis severity and improved quality of life in cancer patients, regardless of their initial xerosis severity or cancer treatment.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This study found that retinoic acid and a retinol complex formulation showed different permeation and compound localization in a skin equivalent model, with unique lipid changes observed with only the retinol formulation.

This study found variation in erythema induction across skin types, suggesting different SSR dose responses and highlighting a potential model for tailoring anti-inflammatory treatments.

In this study, ketoconazole treatment improved acne in all women and reduced hirsutism in some, but it caused several side effects and requires careful monitoring.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This study found that a 1% Sandalore® solution reduced hair shedding and improved hair volume and anagen phase duration in women with telogen effluvium over 24 weeks, compared to placebo.

This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.

This case series found that combining ablative fractional resurfacing and acoustic pressure ultrasound with triamcinolone treatment led to complete recovery in patients with areata alopecia.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.